Noninvasive Liver Fibrosis Testing Starts in the Primary Care SettingTurning the tide against nonalcoholic fatty liver disease (NAFLD)

Prof. Jérôme Boursier, MD, PhD
Faculty of Medicine

University of Angers, Angers, France

|

The disease burden of NAFLD continues to rise, and hepatologists alone cannot evaluate all patients who may be at risk. The ability of primary care physicians to confidently identify and refer NAFLD patients is vital in turning the tide against liver disease.

In this 5-minute video from our expert series on liver disease, watch as Prof. Boursier discusses NAFLD patient management, the challenges faced by general practitioners, and the advantages of using noninvasive testing in the primary care setting.


Prof. Boursier

Jerome Boursier, MD, PhD, is graduated from the Faculty of Medicine of Angers University, in 2006. In 2011, he presented his PhD entitled “Methodology to improve the accuracy of the non-invasive diagnosis of liver fibrosis in chronic hepatitis C”. In 2014, he did a research fellowship in Anna Mae Diehl Lab in Duke University, investigating the area of the gut microbiota and non-alcoholic fatty liver disease. He is Professor of Medicine in the Faculty of Medicine of Angers, since 2016. His main field of research is non-alcoholic fatty liver disease, with an expertise in the non-invasive diagnosis of liver lesions (development of non-invasive tests, pathological significance, diagnostic and prognostic accuracy, relevance in clinical practice). He is the Head of the HIFIH Lab (UPRES 3859, SFR 4208) at Angers University, and the Head of the Hepato-Gastroenterology Department at Angers University Hospital.